Cholesterol metabolism is a potential therapeutic target for Rett syndrome

Clinical Genetics

Volumn 85, Issue 3, 2014, Pages 229-230

  Patankar, J V ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; METHYL CPG BINDING PROTEIN 2; SQUALENE MONOOXYGENASE; TRANSCRIPTION FACTOR SIN3A; CHOLESTEROL;

ADENO ASSOCIATED VIRUS; ARTICLE; BRAIN DISEASE; BREATHING; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHROMATIN STRUCTURE; DERMATITIS; EYE INFLAMMATION; FEMALE; INDUCED MUTATION; MALOCCLUSION; MORBIDITY; MOTOR PERFORMANCE; MOUSE; MUTAGENESIS; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; RETT SYNDROME; SEIZURE; STARTLE REFLEX; TRANSGENIC MOUSE; WALKING DIFFICULTY; X CHROMOSOMAL INHERITANCE; ANIMAL; GENETICS; MALE; METABOLISM; MUTATION;

ANIMALS; CHOLESTEROL; FEMALE; MALE; METHYL-CPG-BINDING PROTEIN 2; MUTATION; RETT SYNDROME;

EID: 84892959609     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12284     Document Type: Article

References (3)

1. Castro J, Mellios N, Sur M. Mechanisms and therapeutic challenges in autism spectrum disorders: insights from Rett syndrome. Curr Opin Neurol 2013: 26 (2): 154-159.
2. Garg SK, Lioy DT, Cheval H et al. Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. J Neurosci 2013: 33 (34): 13612-13620.
3. Lyst MJ, Ekiert R, Ebert DH et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat Neurosci 2013: 16 (7): 898-902.